Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Phasebio Pharmaceuticals Inc (PHAS) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Phasebio Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1169245.
Total stock buying since 2018: $15,225,206.
Total stock sales since 2018: $93,464.
Total stock option exercises since 2018: $331,444.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 0 | $0 | 21,288 | $0 |
| 2022 | 0 | $0 | 11,248 | $8,885 | 0 | $0 |
| 2021 | 13,000 | $39,240 | 9,577 | $26,203 | 81,260 | $156,813 |
| 2020 | 6,000 | $24,720 | 3,497 | $12,064 | 25,846 | $33,322 |
| 2019 | 0 | $0 | 3,308 | $46,312 | 88,044 | $141,309 |
| 2018 | 3,036,500 | $15,161,246 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-05 | 0 | $0 | 0 | $0 | 21,288 | $0 |
| 2022-05 | 0 | $0 | 11,248 | $8,885 | 0 | $0 |
| 2021-11 | 0 | $0 | 5,766 | $13,665 | 61,260 | $132,013 |
| 2021-08 | 13,000 | $39,240 | 0 | $0 | 20,000 | $24,800 |
| 2021-05 | 0 | $0 | 3,811 | $12,538 | 0 | $0 |
| 2020-12 | 6,000 | $24,720 | 0 | $0 | 0 | $0 |
| 2020-11 | 0 | $0 | 3,497 | $12,064 | 0 | $0 |
| 2020-10 | 0 | $0 | 0 | $0 | 5,423 | $6,236 |
| 2020-08 | 0 | $0 | 0 | $0 | 15,000 | $20,850 |
| 2020-02 | 0 | $0 | 0 | $0 | 5,423 | $6,236 |
| 2019-09 | 0 | $0 | 0 | $0 | 19,000 | $23,560 |
| 2019-08 | 0 | $0 | 0 | $0 | 15,000 | $23,475 |
| 2019-07 | 0 | $0 | 2,908 | $40,712 | 0 | $0 |
| 2019-06 | 0 | $0 | 400 | $5,600 | 0 | $0 |
| 2019-05 | 0 | $0 | 0 | $0 | 54,044 | $94,274 |
| 2018-12 | 16,500 | $61,246 | 0 | $0 | 0 | $0 |
| 2018-10 | 3,020,000 | $15,100,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-05-19 | Sapir Alex | Option Ex | 3,750 | .00 | 0 |
| 2023-05-19 | Humphries William D. | Option Ex | 2,538 | .00 | 0 |
| 2023-05-19 | Thorp Clay | Option Ex | 3,750 | .00 | 0 |
| 2023-05-19 | Hutson Nancy J | Option Ex | 3,750 | .00 | 0 |
| 2023-05-19 | Loewy Caroline M | Option Ex | 3,750 | .00 | 0 |
| 2023-05-19 | Harrigan Edmund | Option Ex | 3,750 | .00 | 0 |
| 2022-05-23 | Burkhardt Glen (SVP of Human Resources) | Sale | 11,248 | .79 | 8,885 |
| 2021-11-19 | Burkhardt Glen (VP, Human Resources) | Sale | 5,766 | 2.37 | 13,665 |
| 2021-11-08 | Hutson Nancy J | Option Ex | 7,400 | 3.15 | 23,310 |
| 2021-11-05 | Hutson Nancy J | Option Ex | 26,360 | 2.71 | 71,303 |
| 2021-11-03 | Sharp John P (Chief Financial Officer) | Option Ex | 7,500 | 1.68 | 12,600 |
| 2021-11-03 | Mow Jonathan P (Chief Executive Officer) | Option Ex | 20,000 | 1.24 | 24,800 |
| 2021-08-27 | Mow Jonathan P (Chief Executive Officer) | Option Ex | 20,000 | 1.24 | 24,800 |
| 2021-08-18 | Thorp Clay | Buy | 10,000 | 3.00 | 30,000 |
| 2021-08-18 | Hutson Nancy J | Buy | 3,000 | 3.08 | 9,240 |
| 2021-05-20 | Burkhardt Glen (VP, Human Resources) | Sale | 3,811 | 3.29 | 12,538 |
| 2020-12-03 | Harrigan Edmund | Buy | 6,000 | 4.12 | 24,720 |
| 2020-11-23 | Burkhardt Glen (VP, Human Resources) | Sale | 3,497 | 3.45 | 12,064 |
| 2020-10-01 | Arnold Susan Elizabeth (VP, Preclinical and Chem) | Option Ex | 5,423 | 1.15 | 6,236 |
| 2020-08-21 | Mow Jonathan P (Chief Executive Officer) | Option Ex | 10,000 | 1.24 | 12,400 |
| 2020-08-14 | Sharp John P (Chief Financial Officer) | Option Ex | 5,000 | 1.69 | 8,450 |
| 2020-02-27 | Arnold Susan Elizabeth (VP, Preclinical and Chem) | Option Ex | 5,423 | 1.15 | 6,236 |
| 2019-09-06 | Mow Jonathan P (Chief Executive Officer) | Option Ex | 19,000 | 1.24 | 23,560 |
| 2019-08-21 | Sharp John P (CFO and Secretary) | Option Ex | 15,000 | 1.56 | 23,475 |
| 2019-07-01 | Thorp Clay (Director) | Sale | 2,908 | 14.00 | 40,712 |
| 2019-06-18 | Thorp Clay (Director) | Sale | 400 | 14.00 | 5,600 |
| 2019-05-22 | Sharp John P (CFO and Secretary) | Option Ex | 15,000 | 1.69 | 25,350 |
| 2019-05-20 | Mow Jonathan P (Chief Executive Officer) | Option Ex | 19,131 | 1.24 | 23,722 |
| 2019-05-17 | Mow Jonathan P (Chief Executive Officer) | Option Ex | 19,913 | 2.27 | 45,202 |
| 2018-12-17 | Hutson Nancy J (Director) | Buy | 1,000 | 4.46 | 4,460 |
| 2018-12-13 | Ballance David James (VP, Research and Sci. Affairs) | Buy | 1,000 | 3.94 | 3,940 |
| 2018-12-13 | Mow Jonathan P (Chief Executive Officer) | Buy | 1,000 | 3.69 | 3,690 |
| 2018-12-11 | York Michael (VP, Corporate Development) | Buy | 1,500 | 3.88 | 5,820 |
| 2018-12-10 | Mow Jonathan P (Chief Executive Officer) | Buy | 800 | 3.85 | 3,080 |
| 2018-12-07 | Sharp John P (CFO and Secretary) | Buy | 5,000 | 3.84 | 19,200 |
| 2018-12-07 | Mow Jonathan P (Chief Executive Officer) | Buy | 2,200 | 3.88 | 8,536 |
| 2018-12-04 | Thorp Clay (Director) | Buy | 4,000 | 3.13 | 12,520 |
| 2018-10-22 | Crumpler John (10% Owner) | Buy | 300,000 | 5.00 | 1,500,000 |
| 2018-10-22 | Zeneca, Inc. (10% Owner) | Buy | 600,000 | 5.00 | 3,000,000 |
| 2018-10-22 | Thorp Clay (Director) | Buy | 300,000 | 5.00 | 1,500,000 |
| 2018-10-22 | Viswanathan Ravi (10% Owner) | Buy | 1,800,000 | 5.00 | 9,000,000 |
| 2018-10-22 | Tufts Linda (Director) | Buy | 20,000 | 5.00 | 100,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of PHAS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Phasebio Pharmaceuticals Inc (symbol PHAS, CIK number 1169245) see the Securities and Exchange Commission (SEC) website.